Affordable Access

deepdyve-link deepdyve-link
Publisher Website

In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors
  • Vivash, Lucy1
  • Gregoire, Marie-Claude2
  • Bouilleret, Viviane1
  • Berard, Alexis2
  • Wimberley, Catriona2
  • Binns, David3
  • Roselt, Peter3
  • Katsifis, Andrew2
  • Myers, Damian E1
  • Hicks, Rodney J3
  • O'Brien, Terence J1
  • Dedeurwaerdere, Stefanie4
  • 1 Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia. , (Australia)
  • 2 Department of LifeSciences, Australian Nuclear Science and Technology Organisation, Sydney, New South Wales, Australia. , (Australia)
  • 3 The Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. , (Australia)
  • 4 Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia ; Department of Translational Neurosciences, University of Antwerp, Wilrijk, Belgium. , (Australia)
Type
Published Article
Journal
PLoS ONE
Publisher
Public Library of Science
Publication Date
Jan 01, 2014
Volume
9
Issue
1
Identifiers
DOI: 10.1371/journal.pone.0086722
PMID: 24466212
Source
Medline
License
Unknown

Abstract

Alterations to hippocampal GABAA/cBZR density and affinity in the post-kainic acid SE model of TLE are detectable in vivo with [(18)F]-FMZ PET and a PSM. These changes are independent from hippocampal cell and volume loss. [(18)F]-FMZ PET is useful for investigating the role that changes GABAA/cBZR density and binding affinity play in the pathogenesis of TLE.

Report this publication

Statistics

Seen <100 times